Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
Seagen Inc.
Memorial Sloan Kettering Cancer Center
Jiangsu HengRui Medicine Co., Ltd.
AstraZeneca
M.D. Anderson Cancer Center
ModernaTX, Inc.
Eisai Inc.
Genmab
Quanta Therapeutics
Genentech, Inc.
Replimune Inc.
Debiopharm International SA
Hangzhou Converd Co., Ltd.
Genentech, Inc.
BeOne Medicines
BeOne Medicines
Boehringer Ingelheim
Bright Peak Therapeutics Inc
Tianjin Medical University Cancer Institute and Hospital
Sonnet BioTherapeutics
Gilead Sciences
Guangdong Hengrui Pharmaceutical Co., Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
BioNTech SE
Applied Pharmaceutical Science, Inc.
AstraZeneca
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Boehringer Ingelheim
Seagen Inc.
Instil Bio
Adagene Inc
Suzhou Forlong Biotechnology Co., Ltd
M.D. Anderson Cancer Center
Novartis
D2M Biotherapeutics Inc.
Suzhou Genhouse Bio Co., Ltd.
NeoTX Therapeutics Ltd.
Cullinan Therapeutics Inc.
HiFiBiO Therapeutics
Seattle Children's Hospital
Seattle Children's Hospital
M.D. Anderson Cancer Center
Broadenbio Ltd., Co.
ProDa BioTech, LLC
National Cancer Institute (NCI)
Boehringer Ingelheim